Annual report pursuant to Section 13 and 15(d)

Related Party Transactions - Additional Information (Detail)

v3.20.1
Related Party Transactions - Additional Information (Detail)
9 Months Ended 12 Months Ended
Jul. 24, 2017
USD ($)
shares
Jul. 20, 2017
USD ($)
shares
Jul. 19, 2017
USD ($)
shares
Jul. 18, 2017
USD ($)
shares
Mar. 07, 2017
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2019
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
NotesPayable
Dec. 31, 2018
$ / shares
Jul. 31, 2017
USD ($)
Related Party Transaction [Line Items]                      
Common stock, par value | $ / shares             $ 0.001     $ 0.001  
Ricanto, Ltd [Member]                      
Related Party Transaction [Line Items]                      
Consulting fees incurred, related parties           $ 100,000   $ 0      
Related party consulting agreement, date of termination             Aug. 01, 2017        
Accounts payable, related parties       $ 600,000     $ 0        
Shares issued to related party for services | shares       475              
Ricanto, Ltd [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock [Member]                      
Related Party Transaction [Line Items]                      
Number of shares post-conversion | shares       17,067              
Chief Executive Officer [Member]                      
Related Party Transaction [Line Items]                      
Accounts payable, related parties             0        
Notes payable, related parties                 $ 200,000    
Number of notes payable | NotesPayable                 2    
Notes payable, rate of interest                 3.50%    
Notes payable repayment period                 1 year    
Accrued interest owed to related party             0        
Chief Executive Officer [Member] | Accrued Compensation [Member]                      
Related Party Transaction [Line Items]                      
Accrued salaries, common stock shares issued | shares     238                
Percentage of common stock issued in settlement of accrued salaries     50.00%                
Salary paid     $ 400,000                
Percentage of cash payment in settlement of accrued salaries     50.00%                
Chief Executive Officer [Member] | Convertible Notes Payable [Member]                      
Related Party Transaction [Line Items]                      
Debt conversion, converted instrument, amount $ 200,000                    
Debt conversion, converted instrument, shares issued | shares 146                    
Chief Executive Officer [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock [Member]                      
Related Party Transaction [Line Items]                      
Number of shares post-conversion | shares 5,246   8,551                
Lender [Member]                      
Related Party Transaction [Line Items]                      
Accounts payable, related parties             0        
Notes payable, related parties         $ 20,000            
Notes payable, rate of interest         3.50%            
Notes payable repayment period         1 year            
Accrued interest owed to related party             0        
Debt conversion, converted instrument, amount $ 800,000                    
Debt conversion, converted instrument, shares issued | shares 586                    
Lender [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock [Member]                      
Related Party Transaction [Line Items]                      
Number of shares post-conversion | shares 182,743                    
Chief Financial Officer [Member]                      
Related Party Transaction [Line Items]                      
Accounts payable, related parties             0        
Accrued interest owed to related party             0        
Chief Financial Officer [Member] | Accrued Compensation [Member]                      
Related Party Transaction [Line Items]                      
Accrued salaries, common stock shares issued | shares   127                  
Percentage of common stock issued in settlement of accrued salaries   50.00%                  
Salary paid   $ 200,000                  
Percentage of cash payment in settlement of accrued salaries   50.00%                  
Chief Financial Officer [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock [Member]                      
Related Party Transaction [Line Items]                      
Number of shares post-conversion | shares   4,563                  
Michelle Griffin [Member] | OncoGenex Pharmaceuticals, Inc [Member]                      
Related Party Transaction [Line Items]                      
Termination fee payable                     $ 600,000
Michelle Griffin [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Accrued Liabilities Other [Member]                      
Related Party Transaction [Line Items]                      
Accounts payable, related parties             $ 0